icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
FINDINGS FROM CLINICAL VIROLOGY STUDIES ON ACH-3102 ARE CONSISTENT WITH PRECLINICAL OBSERVATIONS ON ITS IMPROVED POTENCY AGAINST GENOTYPE-1A HCV AND RESISTANT VARIANTS
 
 
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
 
Guangwei Yang, Dharaben Patel, Yongsen Zhao, Joanne Fabrycki, Wengang Yang, Steven Podos, Heather Robison, Lisa Robarge, Hetal Kocinsky, James Hui, Milind Deshpande and Mingjun Huang Achillion Pharmaceuticals, Inc., New Haven, CT
 
Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV
http://www.natap.org/2013/HCV/041613_04.htm

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif